Eikon Therapeutics, Inc. is a pharmaceutical company focused on biomedical research with over $650MM venture capital raised.
Business Challenges
- Manual Financial Statements: Integrating data from multiple platforms required significant manual effort, introducing risk and slowing down
the planning process. - Inefficient Planning Cycles: Legacy processes for OpEx, Workforce, and Capital planning created bottlenecks, limiting agility and
responsiveness. - Limited Granularity & Flexibility: The existing tools lacked bottoms-up planning capabilities and did not allow for high-level overrides by
dimension, such as Account or Department.
Solution
- Automated Data Consolidation: Implemented Anaplan’s Data Hub to aggregate inputs across systems, streamlining financial statement
creation and reducing manual effort. - Targeted, Best-Practice Planning Models:
- OpEx planning leveraged preconfigured drivers.
- Workforce Planning adopted a position-based model for named payroll expenses.
- Capital Planning introduced asset categorization with depreciation based on useful life and straight-line logic.
- Granular Planning with Dimensional Overrides: Enabled bottoms-up planning with the flexibility to apply top-down overrides across key
dimensions (e.g., Account, Department, Cost Center).
Impact
- Improved Efficiency: Reduced reliance on spreadsheets and manual tasks, cutting down planning cycle time.
- Enhanced Accuracy & Control: Enabled detailed, data-driven planning while preserving strategic oversight through high-level dimensional
adjustments. - Greater Agility & Insight: Provided finance teams with real-time access to centralized data, supporting more confident decision-making and
scenario planning aligned to business goals.
